Latest News
EIIB has completed an investment in Rasmala Holdings Limited, an investment bank operating in the Gulf Cooperation Council (GCC) countries and Egypt specialising in asset management, investment banking, brokerage and research.
Rasmala was one of the first regional investment banks to be licensed by the Dubai Financial Services Authority with expertise and relationships in the region maintained through its regulated subsidiaries in the UAE, Saudi Arabia, Egypt and Oman. Rasmala serves a wide range of private and institutional clients including government institutions, corporations, family offices and high net worth individuals. Rasmala employs approximately 140 people in the region.
Rasmala has
The Resolute Fund II, LP, an affiliate of The Jordan Company, has acquired Vantage Specialty Chemicals from HIG Capital. Financial terms of the transaction have not been disclosed.
Headquartered in Chicago, Illinois, Vantage is a diversified specialty chemicals producer focused on naturally derived ingredients. The Company supplies more than 1,500 products to a diverse and growing global customer base within the personal care, consumer products, food and industrial end markets. Vantage’s leading market position is a result of its industry-leading formulation capabilities, efficient and flexible manufacturing facilities, technical support and customer service, broad product offering, global reach and seasoned
NYSE Euronext (NYX), raised more proceeds from Initial Public Offerings (IPOs) than any other global exchange group in 2011, with USD33 billion in total global proceeds raised from 104 IPOs.
In the US, for the fifth consecutive year, NYSE Euronext led the market for IPOs and total proceeds raised with 89 IPOs. Additionally in the US, NYSE gained 16 listing transfers from Nasdaq. In Europe, NYSE Euronext had 44 new listings, with approximately EUR150 million in proceeds raised.
“Despite economic uncertainty and volatile global markets in 2011, NYSE Euronext markets raised more IPO capital than any other venue globally,” says
The fund managed by BNP Paribas Investment Partners’ Clean Energy Partners GP has acquired three wind farm assets in France, bringing its total wind asset base to over 100 mega watts (MW).
The portfolio consists of one asset under construction, “Mazeray” and two assets already in operation: “Coudrays” and “Bois Ballay”. All three assets were developed by a leading wind turbine manufacturer, Nordex. Nordex also provides turbines to many markets globally including Germany, France, Italy, the UK, Scandinavia, China and the US.
Joost Bergsma, CEO of the fund, says: "This acquisition complements our previous wind farm acquisitions in Ireland, the
Ashurst LLP has advised ACG Private Equity and Vivéris Holding on the acquisition of 95% of the shares in Vivéris Management by Vivéris Holding from Caisse d’Epargne Provence Alpes Corse and Financière Mirabel.
Founded in 2000, Vivéris Management is one of the leading French private equity management companies having developed a multi-regional approach targeting private SMEs. Benefiting from an investment team acting in France, in the French Overseas Territories and in the Mediterranean region (Morocco, Tunisia, Turkey), Vivéris Management acts for companies, managers and potential bidders at all stages of their development and on the main areas of the private
Award-winning medical technology spin-out company, Ai2 Limited has secured GBP1.75M in a joint investment from managers of the North West Fund for Biomedical, SPARK Impact and MTI Firms, managers of UMIP Premier Fund.
The deal, which saw MTI invest GBP950k and SPARK Impact, invest GBP800k, allows the Manchester University spin-out to continue development of its cutting edge technology.
The GBP25m North West Fund for Biomedical is part of the GBP185m North West Fund –an evergreen fund provided by the European Investment Bank (EIB) and European Regional Development Fund (ERDF), to supply debt and equity funding to growing small and
AAIPharma Services Corp has acquired Celsis Analytical Services, a division of Celsis International Ltd that performs material testing services for the pharmaceutical, biotechnology and manufacturing sectors.
“The addition of Celsis Analytical Services will enable AAIPharma to expand its market presence in two key regions. Our combined company will bring a differentiated offering to the contract services market with an integrated development and material testing service model,” says Patrick Walsh, CEO of AAIPharma. “We are excited to integrate Celsis labs’ business with AAIPharma, creating one of the largest and most experienced materials testing businesses in the U.S.”
Celsis Analytical Services provides
Normal assumptions about investing in share and bond markets have been turned upside down by Europe’s debt crisis, according to John Chatfeild-Roberts (pictured), Chief Investment Officer and Head of the Jupiter Merlin Independent Funds Team at Jupiter Asset Management…
Making investment decisions has become trickier than ever with the gloomy outlook for the world economy on the one hand, but on the other, attractive valuations of many assets. Markets have swung like a pendulum as investors respond to these opposing pressures.
The start of a New Year changes nothing. 2012 will be a year when investors need what Tolstoy called
Private equity fundraising floundered in the second half of 2011, with the funds that closed in the final quarter of the year raising a similar amount to those closed the previous quarter (USD54.4bn), according to Preqin. However, the firm expects the Q4 figure to increase by around 10-20% and exceed the Q3 total as further information becomes available.
Despite a strong second quarter, in which 189 funds closed having collected USD88.4bn in commitments, the annual total amounted to USD262.6bn, less than the USD274bn raised in 2010, although again Preqin expects the figure to increase to match and perhaps exceed the
Scottish Equity Partners (SEP) has announced the successful close of its new growth equity and venture capital fund, SEP IV, confirming that it had reached its GBP200 million target by the end of 2011.
The fund, which ranks as one of the largest raised in Europe over the last year, attracted very strong support, defying the generally difficult climate for private equity fundraisings. SEP’s existing investors accounted for 80% of the total raised. Approximately half of the fund was accounted for by UK-based investors, with the remaining 50% coming from investors based in Europe and the United States.
Investors in
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
